Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy

Дата публикации: 18-08-2026 00:00:00

This cross-sectional study explores the 2026 guideline on dyslipidemia management, examining the population health impact on US adults recommended primary prevention statin therapy due to atherosclerotic cardiovascular disease risk.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Prevalence of LDL-C Above 2026 Dyslipidemia Guideline Goals Among US Adults	0	20.18	18-08-2026
2	Cardiovascular Risk Reclassification With the 2026 Dyslipidemia Guideline	0	11.38	18-08-2026
3	Dyslipidemia Evaluation and Management	0	11.26	18-08-2026
4	New Dyslipidemia Guidelines Lower the Lipid Treatment Goals and Raise the Bar for Clinical Practice	0	6.02	18-08-2026
5	Global Burden of Elevated LDL-C	0	10.09	29-07-2026
6	Dyslipidemia and risk of incident stroke: the mediating role of insulin resistance assessed by the triglyceride–glucose index in the CHARLS cohort	0	5	14-07-2026
7	Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults	0	20.39	04-06-2024
8	Association of Cumulative Exposure and Dynamic Trajectories of C-Reactive Protein-Triglyceride-Glucose Index with Incident Cardiovascular-Kidney-Metabolic Syndrome Stage 4: A Nationwide Cohort Study from CHARLS	0	7	15-07-2026
9	Spectrum of Aldosteronism and Cardiovascular Outcomes	0	6.27	01-04-2026
10	Statins may help almost everyone with type 2 diabetes live longer	0	10.99	15-01-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.25. Источник: archderm.jamanetwork.com.